Table 3.
Neutralization of TcdB by humanized antibody mixtures
| MAb or combination (ratio) | Neutralization of TcdB (EC50 [ng/ml]) ata: |
||
|---|---|---|---|
| LD60 | LD77 | LD85 | |
| CA1125 + CA1134 (25:75) | <0.15 | 0.84 | 7.2 |
| CA1125 + CA1134 (50:50) | 0.48 | 1.4 | 4 |
| CA1125 + CA1134 (75:25) | 0.66 | 1.2 | 2.5 |
| CA1125 + CA1151 (25:75) | 0.73 | 1 | 2.1 |
| CA1125 + CA1151 (50:50) | 0.85 | 0.85 | 1.5 |
| CA1125 + CA1151 (75:25) | 1.4 | 1.2 | 8.3 |
| CA1125 + CA1153 (25:75) | 7 | 10 | 27 |
| CA1125 + CA1153 (50:50) | 2.7 | 5.2 | 25.2 |
| CA1125 + CA1153 (75:25) | 2.9 | 7.5 | 30 |
| MDX-1388 | 2.2 | 2.5 | 7.7 |
a
All data represent one experiment each of three assay replicates. The relative and absolute EC50s are representative of two additional independent assays each of three assay replicates, where the TcdB LD values differ by <20% due to interassay variability of TcdB toxicity to Caco-2 cells.